Skip to main content

TNF-α regulates diabetic macrophage function through the histone acetyltransferase MOF.

Citation
denDekker, A. D., et al. “Tnf-Α Regulates Diabetic Macrophage Function Through The Histone Acetyltransferase Mof.”. Jci Insight.
Center University of Michigan
Author Aaron D denDekker, Frank M Davis, Amrita D Joshi, Sonya J Wolf, Ronald Allen, Jay Lipinski, Brenda Nguyen, Joseph Kirma, Dylan Nycz, Jennifer Bermick, Bethany B Moore, Johann E Gudjonsson, Steven L Kunkel, Katherine A Gallagher
Keywords diabetes, immunology, inflammation, macrophages
Abstract

A critical component of wound healing is the transition from the inflammatory phase to the proliferation phase to initiate healing and remodeling of the wound. Macrophages are critical for the initiation and resolution of the inflammatory phase during wound repair. In diabetes, macrophages display a sustained inflammatory phenotype in late wound healing characterized by elevated production of inflammatory cytokines, such as TNF-α. Previous studies have shown that an altered epigenetic program directs diabetic macrophages toward a proinflammatory phenotype, contributing to a sustained inflammatory phase. Males absent on the first (MOF) is a histone acetyltransferase (HAT) that has been shown be a coactivator of TNF-α signaling and promote NF-κB-mediated gene transcription in prostate cancer cell lines. Based on MOF's role in TNF-α/NF-κB-mediated gene expression, we hypothesized that MOF influences macrophage-mediated inflammation during wound repair. We used myeloid-specific Mof-knockout (Lyz2Cre Moffl/fl) and diet-induced obese (DIO) mice to determine the function of MOF in diabetic wound healing. MOF-deficient mice exhibited reduced inflammatory cytokine gene expression. Furthermore, we found that wound macrophages from DIO mice had elevated MOF levels and higher levels of acetylated histone H4K16, MOF's primary substrate of HAT activity, on the promoters of inflammatory genes. We further identified that MOF expression could be stimulated by TNF-α and that treatment with etanercept, an FDA-approved TNF-α inhibitor, reduced MOF levels and improved wound healing in DIO mice. This report is the first to our knowledge to define an important role for MOF in regulating macrophage-mediated inflammation in wound repair and identifies TNF-α inhibition as a potential therapy for the treatment of chronic inflammation in diabetic wounds.

Year of Publication
2020
Journal
JCI insight
Volume
5
Issue
5
Date Published
03/2020
ISSN Number
2379-3708
DOI
10.1172/jci.insight.132306
Alternate Journal
JCI Insight
PMID
32069267
PMCID
PMC7141388
Download citation